Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 9;6:91. doi: 10.1038/s41698-022-00334-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Kaplan Meier curves for real world overall survival (rwOS) are shown with univariate (top) and multivariate (bottom) analysis tables for each disease subtype. Analysis was performed using the Flatiron Health-Foundation Medicine real-world clinicogenomic database. Patients with multiple driver alterations spanning >1 category were excluded. a In patients with advanced NSCLC harboring KRAS G12C mutant tumors have similar rwOS to other KRAS G12/13, KRAS non-G12/G13C, and driver negative patients. b In metastatic CRC, patients with KRAS G12C had similar rwOS compared to other KRAS mutant isoforms, BRAF V600E, and NRAS mutations, but worse rwOS compared to patients negative for KRAS and NRAS mutations and BRAF V600E (RAS/RAF negative). c In metastatic PDAC, rwOS was marginally inferior for KRAS G12C vs KRAS WT, although the differences were small and were not observed in the multivariable model.